Innovating Works

ALACRIS

A stranger
3TR: Identification of the Molecular Mechanisms of non response to Treatments Relapses and Remission in... ALACRIS THERANOSTICS GMBH participó en un H2020 H2020-JTI-IMI2-2018-14-two-stage 3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions...
2019-08-22 - 2026-08-31 | financed
iPC: individualizedPaediatricCure Cloud based virtual patient models for precision paediatric oncology ALACRIS THERANOSTICS GMBH participó en un H2020 H2020-SC1-DTH-2018-2020 Effective personalized medicine for paediatric cancers must address a multitude of challenges, including domain-specific challenges. To over...
2018-12-19 - 2023-11-30 | financed
TAPAS: TArgeting Platelet Adhesion receptors in thrombosiS ALACRIS THERANOSTICS GMBH participó en un H2020 H2020-MSCA-ITN-2017 TAPAS will position Europe at the forefront of innovative research to prevent thrombosis and thromboinflammation, and will train a uniquely-...
2017-08-17 - 2022-06-30 | financed
CanPathPro: Generation of the CanPath prototype a platform for predictive cancer pathway modeling ALACRIS THERANOSTICS GMBH processed a H2020 H2020-BIOTEC-2014-2015 Recent developments in omics technologies demand implementation of systems biology approaches to facilitate analysis and interpretation of t...
2016-02-25 - 2021-11-30 | financed
SMARTool: Simulation Modeling of coronary ARTery disease a tool for clinical decision support ALACRIS THERANOSTICS GMBH participó en un H2020 H2020-PHC-2014-2015 SMARTool aims at developing a platform based on cloud technology, for the management of patients with coronary artery disease (CAD) by stand...
2015-11-11 - 2019-06-30 | financed
PROSEQO: PROtein SEQuencing using Optical single molecule real time detection ALACRIS THERANOSTICS GMBH participó en un H2020 H2020-FETOPEN-2014-2015 The advent of analytical techniques with extremely low limits of detection has led to dramatic progresses mostly in the field of nucleic aci...
2015-11-03 - 2019-02-28 | financed
TREGeneration: Repair of tissue and organ damage in refractory chronic graft versus host disease after hematopoieti... ALACRIS THERANOSTICS GMBH participó en un H2020 H2020-PHC-2014-2015 Our proposal encompasses parallel clinical trials addressing the feasibility and the effectiveness of donor-derived regulatory T cells (Treg...
2014-12-01 - 2021-12-31 | financed
CANCER-ID: Cancer treatment and monitoring through identification of circulating tumour cells and tumour relate... ALACRIS THERANOSTICS GMBH participó en un FP6 Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential...
2015-01-01 - 2019-12-31 | financed
ONCOTRACK: OncoTrack - Methods for systematic next generation oncology biomarker development ALACRIS THERANOSTICS GMBH participó en un FP6 We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients wit...
2011-01-01 - 2016-12-31 | financed
CANCER-ID: Cancer treatment and monitoring through identification of circulating tumour cells and tumour relate... ALACRIS THERANOSTICS GMBH participó en un FP7 Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential...
financed
ONCOTRACK: OncoTrack Methods for systematic next generation oncology biomarker development ALACRIS THERANOSTICS GMBH participó en un FP7 We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients wit...
financed
ITFoM: IT Future of Medicine ALACRIS THERANOSTICS GMBH participó en un FP7 Data-rich, individualised medicine poses unprecedented challenges for IT, in hardware, storage and communication. We propose a data-driven,...
financed
SYBIL: Systems biology for the functional validation of genetic determinants of skeletal diseases ALACRIS THERANOSTICS GMBH participó en un FP7 "The aim of SYBIL is to carry out extensive functional validation of the genetic determinants of rare and common skeletal diseases and the a...
financed
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.